Comparison of two immunoassays for measurement of faecal calprotectin in detection of inflammatory bowel disease: (pre)-analytical and diagnostic performance characteristics

Oyaert, Matthijs; Trouve, Charlotte; Baert, Filip; Smet, Dieter De; Langlois, Michel; Vanpoucke, Hilde

doi:10.1515/cclm-2013-0699

Cited by 38 publications

(32 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…CI, confidence interval; SE, standard error. Along with non-standardisation between the different faecal calprotectin assays, pre-analytical issues of faecal calprotectin analyses can contribute to the (often large) variation in faecal calprotectin concentrations between different assays [6,7,10,26]. In this study, all faecal samples where appropriately homogenised and weighed before extraction.…”

Section: Discussionmentioning

confidence: 99%

“…Consequently, faecal calprotectin concentration may be related to inflammation of the bowel mucosa in IBD. Despite some analytical and pre-analytical drawbacks [6][7][8][9][10], encouraging data have recently been published about the clinical efficacy of this biomarker for monitoring disease activity, response to treatment and relapse [11,12]. In addition, faecal calprotectin is resistant to bacterial degradation, being stable in stool for up to 3 days at room temperature, which adds more benefits to its use as a laboratory marker [13].…”

Section: Introductionmentioning

confidence: 99%

“…Over the past years, different assays for the detection of faecal calprotectin have been introduced including point-of-care methods [7,[14][15][16][17][18][19][20][21]. These methods have the advantage of being easy to use and allowing analysis as soon as the sample is received in the laboratory.…”

Section: Introductionmentioning

confidence: 99%

“…In addition, results are rapidly available, which allows quick clinical decision making. However, as laboratories are being consolidated, more automated assays such as enzyme-linked immunoassays (ELISA) [7,22,23], chemiluminescence immunoassays (CLIA), fluoro enzyme immunoassays (FEIA) and particle enhanced turbidimetric immunoassays (PETIA) for the measurement of faecal calprotectin have been introduced [10].…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Analytical performance and diagnostic accuracy of six different faecal calprotectin assays in inflammatory bowel disease

Oyaert

Boel

Jacobs

et al. 2017

Clinical Chemistry and Laboratory Medicine (CCLM)

Self Cite

View full text Add to dashboard Cite

Background: We evaluated the analytical performance of six different faecal calprotectin immunoassays together with their diagnostic accuracy in the discrimination between functional and organic bowel disorders. Methods: The faecal samples were obtained from inflammatory bowel disease patients (n = 27) at the time of diagnosis [Crohn's disease (n = 15), colitis ulcerosa (n = 12)], gastroenterologic disease control patients (n = 52) and rheumatologic disease control patients (n = 26). All individuals included in the study underwent a concurrent ileocolonoscopy. Analytical performance (imprecision, accuracy, carry-over, correlation and agreement) and diagnostic accuracy (sensitivity, specificity, likelihood ratios) of the different assays were evaluated. Results: All methods demonstrated good analytical performance, but within-run and total imprecision varied depending on the assay methodology used. Using Passing Bablok and Bland-Altman analyses, low quantitative agreement was observed between the assays. All assays showed excellent diagnostic accuracy, with areas under the receiver operating characteristic curves (ROC) ranging from 0.974 to 0.998. The AUCs were not significantly different between assays (p > 0.05). Diagnostic sensitivity at the

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Analytical performance and diagnostic accuracy of six different faecal calprotectin assays in inflammatory bowel disease

Oyaert

Boel

Jacobs

et al. 2017

Clinical Chemistry and Laboratory Medicine (CCLM)

Self Cite

View full text Add to dashboard Cite

show abstract

“…A meta-analysis of eight studies totaling 1062 subjects recently concluded that a patient with a fecal calprotectin value ≤ 40 μg/g has a 1% probability of having IBD and a 84.1% probability of being healthy [5], thus exhibiting better diagnostic performance than C-reactive protein, erythrocyte sedimentation rate and fecal lactoferrin for ruling out this condition. Despite some analytical and preanalytical drawbacks remain [6][7][8][9], encouraging data has also been recently published about the clinical efficacy of this biomarker for monitoring disease activity, response to treatment and relapse [10,11].…”

mentioning

confidence: 99%

Biomarkers of inflammatory bowel disease: ready for prime time?

Plebani

Basso

Lippi

2015

Clinical Chemistry and Laboratory Medicine (CCLM)

View full text Add to dashboard Cite

Fecal calprotectin correlates with active colonic inflammatory bowel disease but not with small intestinal Crohn's disease activity

et al. 2018

View full text Add to dashboard Cite

BackgroundThe utility of fecal calprotectin (FC) in small intestinal Crohn's disease (CD) is unclear. We examined how reliably FC reflects clinical and mucosal disease activity in small intestinal CD, colonic CD, and ulcerative colitis (UC).MethodsA total of 72 Inflammatory Bowel Disease (IBD) patients (23 colonic CD, 14 isolated small intestinal CD, and 35 UC) were included. Clinical activity was assessed using the Harvey–Bradshaw Index (HBI) (CD) and Mayo score (UC). Inflammatory activity was assessed through ileocolonoscopy, cross‐sectional imaging, C‐reactive protein (CRP), and FC. Clinical activity was defined as HBI > 4 or Mayo clinical score ≥ 3. Endoscopy activity was defined as Mayo endoscopic subscore ≥ 1, SES‐CD score ≥ 3, and Rutgeerts > i1.ResultsIn UC, FC was correlated with the Mayo clinical score (P < 0.0001) and was highly correlated with the total Mayo score (P < 0.0001). A cut‐off value of FC 100 μg/g provided sensitivity of 88% and specificity 100% for endoscopic activity. FC was lower for patients with endoscopic and clinical remission compared to active endoscopic disease (median 100 vs 1180 μg/g, P < 0.0001). In colonic CD, there was a significant correlation between FC and endoscopic activity (P < 0.001). For an FC cut‐off value of 100 μg/g, sensitivity was 100%, and specificity was 67%. In contrast, for isolated small intestinal CD, there was no significant correlation between FC and objective disease activity measured by either endoscopy or imaging (AUC 0.52, P = 0.58).ConclusionFC is reliable for the detection of colonic mucosal inflammation in both UC and CD but is less sensitive and reliable in the detection of small intestinal CD.

show abstract

Comparison of two immunoassays for measurement of faecal calprotectin in detection of inflammatory bowel disease: (pre)-analytical and diagnostic performance characteristics

Abstract: The Thermo Fisher device is not reliable for extraction of faecal calprotectin. The performance characteristics of the EliA Calprotectin assay are statistically equivalent to the Bühlmann POCT.

Cited by 38 publications

References 19 publications

Analytical performance and diagnostic accuracy of six different faecal calprotectin assays in inflammatory bowel disease

Analytical performance and diagnostic accuracy of six different faecal calprotectin assays in inflammatory bowel disease

Biomarkers of inflammatory bowel disease: ready for prime time?

Fecal calprotectin correlates with active colonic inflammatory bowel disease but not with small intestinal Crohn's disease activity

Contact Info

Product

Resources

About